



Where Science is Supported/Companies are Created/Drugs are Developed/Patients are Paramount

# BioLines Weekender

## To Our New Jersey Life Sciences Community: Welcome to another edition of the Weekender.

### **BIG News for New Jersey Drug Approvals This Week**

BioNJ Member **The Medicines Company** announced the approval of KENGREAL™ (cangrelor) by the FDA as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI). This is the third approval for The Medicines Company this year!



**Eisai Inc.** has received approval from the FDA for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa® (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older.

European regulators have issued a green light for BioNJ Member **Bristol-Myers Squibb's** Opdivo as a treatment for advanced skin cancer, making it the first PD-1 inhibitor to win approval in the region.

### **Biosimilars Legislation Passes the Senate**

Legislation on biosimilar products passed the Senate unanimously on Thursday, June 25. The pending legislation allows some biosimilars to be substituted for biological products, but only if the FDA has approved them as interchangeable with the innovator product. Additionally, pharmacists must notify prescribing physicians of the substitution. This legislation -- over a year in the making -- represents a thoughtful, balanced approach to providing new medicines while protecting patient safety. Passage of this bill and its signing into law by the Governor will bring new hope to the thousands of patients and their families who are waiting for new treatments and cures.

### **It's an Exciting Time to Be Involved in Biotech in New Jersey**

New Jersey's dynamic life sciences community is featured in an article released yesterday by *BioSpace*. [Click here](#) for the story and to see how New Jersey stacks up against other states on drug approvals! Way to go New Jersey!

### **BIO 2015 Closes in Philadelphia With More Than 15,800 Attendees**

BioNJ would like to thank the Biotechnology Innovation Organization (BIO), Choose New Jersey and the State of New Jersey for an amazing partnership, as well as New Jersey's Host Committee for all of your hard work and incredible collaboration in making BIO 2015 a HUGE SUCCESS for the entire region. [Click here](#) for the list of 179 Host Committee Members from New Jersey. And, [click here](#) for the BIO 2015 New Jersey Recap and Wrap Up.

*Because Patients Can't Wait,*

The BioNJ Team

[Click here](#) to forward this issue of the *Biolines Weekender* to your colleagues.

Please send us your press releases at [BioNJ@BioNJ.org](mailto:BioNJ@BioNJ.org) to be included in the *Weekender*.

Do you know someone who wants to receive BioNJ information?  
Have them email [BioNJ@BioNJ.org](mailto:BioNJ@BioNJ.org) to be put on our mailing list.

## BioNJ Calendar

### ***NewX2 BioCruise***

July 15, 2015  
New York Harbor World Yacht at Pier 81

Register [here](#) for this event.

### ***CEO Summit***

October 8-9, 2015  
Bridgewater Marriott

Registration coming soon!

## *BioNJ News*

### **Berkley Life Sciences Vanguard Award**



BioNJ is so honored to have received the inaugural Berkley Life Sciences Vanguard Award for service to the NJ life sciences community. Thank you to CEO and President, Jill Wadlund; VP, Strategic Business Development, John Morel; and the entire team at Berkley Life Sciences for naming their incubator classroom for BioNJ and for hosting an amazing event on Tuesday, June 23, at their beautiful Ewing office.

### **BioNJ Says Farewell to Jim Marino as a Treasured Board Member**

Having been at the table since Day 1, BioNJ's beloved and trusted legal (and many other things) Advisor Jim Marino is retiring from the Board as he withdraws from Dechert on June 30, 2015 where he served as a partner for 28 years. While at Dechert, Jim built one of the leading life sciences practices in our region. Thank you, Jim, for your time, leadership and wealth of expertise and guidance. You will be missed.

## *BioNJ in the News*

### **Exciting Time for Biotech in New Jersey**

The Garden State is home to more than 3,000 establishments in the pharma, medtech and life sciences industries -- and that number is poised to grow in the future, according to BioNJ, a trade group for research-based life sciences companies. Thanks to facility expansions, acquisitions, and research institution mergers, along with an increase in companies moving or beginning operations in New Jersey, the area is seeing a surge in activity for biotech.

Please [click here](#) for the full article.

### **Discover Biotech's Most Influential**

BioNJ President and CEO Debbie Hart, along with five other New Jersey executives, including Bob Hugin, Chairman and CEO, Celgene; Sol Barer, Ph.D., Founder, Celgene, and Managing Partner, SJ Barer Consulting; Robert Hariri, M.D., Ph.D., Chairman and Founder, Celgene Cellular Therapeutics; Paul Stoffels, M.D., CSO, Johnson & Johnson; and Shirley Tilghman, Ph.D., Professor, Molecular Biology, Princeton University, were named to the Worldview 100 as six of the 100 most influential people in biotechnology.

Please [click here](#) for the full article.

### **The 2015 BIO International Convention Closes in Philadelphia - Event Sets New Record for Partnering Meetings**

The 2015 BIO International Convention, where the global biotech community meets, connecting the people, companies and innovations that help to fulfill the promise of biotechnology through healing, fueling and feeding the world, concluded June 18 at the Pennsylvania Convention Center. This year's Convention hosted 29,279 partnering meetings -- a new record. The event drew 15,858 industry leaders from 69 countries and 47 states, as well as the District of Columbia and Puerto Rico.

Please [click here](#) for the full press release.

# *Putting Patients First: The Value of Medical Innovation*

*Brought to You by Celgene Corporation*

## **Wage Hope in the Fight Against Pancreatic Cancer**

When my father, Jim Fleshman, was diagnosed with pancreatic cancer in 1999, he was told -- unequivocally -- that he was going to die. He was given no options for treatment, no information or support, no hope. Armed only with grief, my family got his affairs in order, and four short months later, I lost one of the most important figures in my life. My father was only 52 when he lost his battle against one of the nation's deadliest cancers.

But today, there is a difference -- there is hope. The Pancreatic Cancer Action Network is offering hope by providing patients and families with vital resources and information on treatment options.

Please [click here](#) for the full article.

## **The Quickening Pace of Medical Progress and Its Discontents**

Against the backdrop of current controversies over drug pricing and access to new medical breakthroughs is a transformation in the relationship between basic science and the practice of medicine. The pace at which fundamental discoveries of basic science are being uncovered is accelerating, as is the speed at which medical practice is being transformed by these inventions. Metamorphic changes are sweeping a wider breadth of clinical areas more regularly than at any time in the history of science. Creative destruction is an increasingly prominent feature of modern medical practice.

Please [click here](#) for the full article.

## *NJ Industry News*

### **The Medicines Company Announces FDA Approval of KENGREAL™ (cangrelor) as an Adjunct to Percutaneous Coronary Intervention (PCI) for Reducing Thrombotic Events**

Parsippany-based BioNJ Member The Medicines Company announced on June 22 the approval of KENGREAL™ (cangrelor) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI). This is the third U.S. drug approval for The Medicines Company this year, including RAPLIXA™ and IONSYS®. Additionally, they had a new formulation of MINOCIN® for injection approved earlier this year.

[Click here](#) for the full press release on KENGREAL™.

[Click here](#) for the full press release on RAPLIXA™.

[Click here](#) for the full press release on IONSYS®.

### **U.S. FDA Approves Eisai's Antiepileptic Agent FYCOMPA® as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures**

Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa® (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older.

Please [click here](#) for the full press release.

### **BMS' Opdivo First EU Approved PD-1 inhibitor**

European regulators have issued a green light for BioNJ Member Bristol-Myers Squibb's Opdivo as a treatment for advanced skin cancer, making it the first PD-1 inhibitor to win approval in the region.

Please [click here](#) for the full press release.

### **First Lady Mary Pat Christie and Health Commissioner Mary O'Dowd Announce \$4.4 Million in Grants for Autism Medical Homes and Expansion of Autism Research**

Enhancing the administration's firm commitment to finding new and innovative ways to help New Jersey families impacted by autism, First Lady Mary Pat Christie and Health Commissioner Mary E. O'Dowd today announced \$4.4 million in grants to establish Autism Medical Homes and the advance research in the understanding, prevention, evaluation and treatment of the biologically-

based disorder. New Jersey is a national leader in early intervention and education of children with autism which affects about 1 in 45 children across the Garden State.

Please [click here](#) for the full press release.

### **Middlesex County's VaxInnate Uses State Support in its Quest to Prevent Infectious Diseases**

Continuing New Jersey's long-standing tradition of being a leader in technology, companies in the Garden State are seen as innovators in addressing today's health threats. With the onset of new viruses, companies such as Cranbury-based BioNJ Member VaxInnate Corporation are racing to stay ahead by developing state-of-the-art vaccinations.

Please [click here](#) for the full article.

### **NJBIZ Healthcare Heroes Winners Named**

Congratulations to BioNJ Chairman of the Board Stuart Peltz, CEO, PTC Therapeutics, for being a NJBIZ Innovation Hero Finalist.

We are proud of all of the BioNJ Members who were recognized on the Healthcare Heroes list, including Jeffrey Boscamp, Shafiq Rab, Rosemary Hunt, Dr. Joseph Feldman and Kate McDougall from Hackensack University Medical Center and Robert C. Garrett from Hackensack University Health Network, as well as Member organizations that made the list, including Rutgers Robert Wood Johnson Medical School and Fairleigh Dickinson University School of Pharmacy.

[Click here](#) to read the full article.

### **Hackensack University Medical Center is First Hospital to Join the American Sustainable Business Council**

On June 24, the American Sustainable Business Council announced that BioNJ Member Hackensack University Medical Center has joined as a business member. HackensackUMC is the first hospital to join ASBC, which works on policy changes that move the economy towards more social, economic and environmental sustainability.

Please [click here](#) for the full article.

### **CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination Including TRUMENBA® for Adolescents and Young Adults 16 Through 23 Years of Age**

BioNJ Member Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers.

Please [click here](#) for the full press release.

### **Pfizer Announces Enrollment of First Patient in Phase 3 Trial in Sickle Cell Disease**

BioNJ Member Pfizer Inc. announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study -- a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older.

Please [click here](#) for the full press release.

### **Soligenix Announces Collaboration With the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma**

Princeton-based BioNJ Member Soligenix, Inc., a late-stage biopharmaceutical company who develops products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced that it will be working with the National Organization for Rare Disorders (NORD) and the Cutaneous Lymphoma Foundation (CLF) to educate and recruit patients for its pivotal Phase 3 clinical study of SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).

Please [click here](#) for the full press release.

### **UPDATE: > 100 for #Cures2015**

The 21st Century Cures Act continues to enjoy growing support from individuals and groups all across the country.

Seventy-five research, life sciences and patient advocacy organizations recently joined the wave of support voicing their approval of the legislation in a letter.

Please [click here](#) for the full press release.

## **Advaxis Selected for Inclusion in Russell Global and Russell 3000® Indexes**

Princeton-based BioNJ Member Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced on June 22 that the company will be added to the Russell Global and Russell 3000® Indexes. This inclusion will become effective upon the close of trading on June 26, when the Russell Investment Group reconstitutes its comprehensive set of U.S. and global indexes, according to a preliminary list of additions posted on June 12.

Please [click here](#) for the full press release.

## **Stop Signs: Father of the Year Awards Celebrate Outstanding Dads, Community Leaders**

Father of the Year Awards dinners are hosted in more than 30 cities across the country in a collaboration between the American Diabetes Association and the National Father's Day Council. Every year, the council in each city conducts a nomination process to identify honorees. Awardees are selected because their peers and family recognize them as role model fathers and community leaders who are committed to helping fund diabetes research, education and advocacy programs.

Please [click here](#) for the full article.

## **Q and A with Dr. Heinrich of New Jersey Health Foundation**

NJBIZ talks with Dr. George F. Heinrich, Vice Chair and Chief Executive Officer of Foundation Venture Capital Group, a position he also holds with New Jersey Health Foundation.

Please [click here](#) for the full article.

# *University/Institution News*

## **Rutgers University Touts Bacteria That Breathes Uranium**

New Brunswick-based BioNJ Member Rutgers University announced that a team of university scientists had isolated a strain of bacteria that "breathes" uranium, which may make it invaluable in decontaminating groundwater at sites like uranium mills where radioactive material was processed for nuclear weapons.

Please [click here](#) for the full article.

## **Rutgers Cancer Institute of New Jersey Physicians Named Among 'Top Docs' in the State for Cancer Care**

Several physicians at BioNJ Member Rutgers Cancer Institute of New Jersey have been named as a 'Top Doctor for Cancer Care' by *Inside Jersey* magazine. Each year, *Inside Jersey* releases a list of the state's top physicians for cancer care in conjunction with Castle Connolly Medical Ltd., which publishes America's Top Doctors. Based on peer surveys, attributes such as board certification, clinical skills, training, years in practice, administrative posts, achievements and other criteria are reviewed and assessed by a physician-led research team assembled by Castle Connolly. Cancer Institute of New Jersey physicians are among a select group this year.

Please [click here](#) for the full article.

## **Autophagy Defect Explored in Hereditary Breast Cancer**

New Brunswick-based BioNJ Member Rutgers Cancer Institute of New Jersey researchers Bing Xia, Ph.D., and Eileen P. White, Ph.D., have been awarded a \$2.4 million R01 grant (R01CA188096) from the National Cancer Institute (NCI) to explore the relationship between the cellular-survival mechanism of autophagy and tumor suppression function in hereditary breast cancers.

Please [click here](#) for the full press release.

## **Introduction to Biotechnology by Dr. Palladino, Dean, Monmouth University of Science Used at Over 150 Institutions**

Dr. Palladino is the co-author, with Bill Thieman, of *Introduction to Biotechnology* an undergraduate textbook that is currently used at over 150 institutions throughout the United States and Canada as well as Australia, China, Germany, India, New Zealand, Pakistan, Singapore and the United Kingdom. Now in its third edition, *Introduction to Biotechnology* has been translated in Chinese, German, Korean, Spanish and Taiwanese and is the leading textbook worldwide in undergraduate biotechnology education.

[Click here](#) to learn more.

## *Resources for Entrepreneurs*

### **2015 Technology Business Tax Certificate Transfer Program Webpage and Application Open**

Administered by the New Jersey Economic Development Authority in consultation with the New Jersey Division of Taxation, the program offers a 10 percent refundable tax credit against New Jersey corporation business or gross income tax for qualified investments in an emerging technology business with a physical presence in New Jersey and that conducts research, manufacturing, or technology commercialization in the state. The program is available to all eligible taxpayers, including out of state investors.

Please [click here](#) for more information.

### **The 2015 HHS SBIR/STTR Omnibus Grant Solicitations are now live!**

The Department of Health and Human Services (HHS) has just released the 2015 Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Omnibus Grant Solicitations! These solicitations will be used by the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and the Administration for Children and Families (ACF).

Please [click here](#) for more information.

## *BioNJ Purchasing Consortium*

### **BioNJ's Purchasing Consortium: Enhanced Member Benefits, Saving Money and Time, Helping You Help Patients**

Through [BioNJ's Purchasing Consortium](#), our Members have access to programs and services negotiated by BioNJ and BIO and offered at favorable rates and terms to save your company money. Through our affiliation with BIO, BioNJ is part of the largest cost-savings program for the life science industry with the purchasing power of over 2,800 biotech companies. Our group discounts are for Members only and your Membership is the gateway to this purchasing power to save your company critical resources.


For more information on how you can sign up for these Member discounts and save your working capital, contact Linda Pontell, Director of Marketing, Member Services at [LPontell@BioNJ.org](mailto:LPontell@BioNJ.org).

## *BioNJ Talent Services*

### **Job Leads**

Please [click here](#) to see the list of available jobs from companies such as such as Covance, Merck, Novo Nordisk, GENEWIZ, Amicus Therapeutics and Allergan.

## *BioNJ Tweets of the Week*



Please contact BioNJ at [BioNJ@BioNJ.org](mailto:BioNJ@BioNJ.org)

or [609-890-3185](tel:609-890-3185) with any questions.

Connect with us:

